Collegium Pharmaceutical

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Our mission is to provide innovative solutions to address unmet medical needs. We will pursue innovative solutions to meet healthcare need, remain focused on the success of the patient, and sustain excellence in the development of medications.

Our vision is to become a leader in the development and commercialization of products by utilizing our proprietary DETERx platform technology.

Collegium has won numerous awards since its founding, including the 2013 Massachusetts Innovation and Technology Exchange Award, two 2013 Frost & Sullivan Awards, and a New England Innovation Award in 2011.